Vaskulárna medicína 1-2/2012
New antiplatelet agents for clinical practise
Atherotrombotis vascular disease is leading cause of morbidity and mortality, accounting for approximately 40 % of all death in western countries. As platelets play a pivotal role in the pathogenesis of atherothrombosis. Pharmaceutical research has focused on the development of antiplatelet drugs. A number of novel drugs, currently under evaluation in clinical trials, have been developed. These include prasugrel, ticagrelol, cangrelor , SCH 53048 and terutroban.
Keywords: antiplatelet drugs, prasugrel, ticagrelol, cangrelor, SCH 53048, terutroban.
